Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial-Reference-Cited by-同舟云学术

Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial

Published:2023-11 Issue:11 Volume:24 Page:1266-1276
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Aggarwal Rahul,Starzinski Stephanie,de Kouchkovsky Ivan,Koshkin Vadim,Bose Rohit,Chou Jonathan,Desai Arpita,Kwon Daniel,Kaushal Samuel,Trihy Lauren,Rastogi Medini,Ippisch Robin,Aslam Maya,Friedlander Terence,Feng Felix,Oh David,Cheung Alexander,Small Eric,Evans Michael,Fong Lawrence,Hope Thomas A

Funder

Merck

Novartis Pharmaceuticals Corporation

National Cancer Institute

Prostate Cancer Foundation

Publisher

Elsevier BV

Subject

Oncology

Reference26 articles.

1. The hallmarks of successful anticancer immunotherapy;Galluzzi;Sci Transl Med,2018

2. Comparative effectiveness of immune checkpoint inhibitors vs chemotherapy by tumor mutational burden in metastatic castration-resistant prostate cancer;Graf;JAMA Netw Open,2022